Surveillance for lung metastasis from giant cell tumor of bone

2017 ◽  
Vol 116 (7) ◽  
pp. 907-913 ◽  
Author(s):  
Mamer Rosario ◽  
Han-Soo Kim ◽  
Ji Yeon Yun ◽  
Ilkyu Han
2017 ◽  
Vol 7 ◽  
pp. 23-28 ◽  
Author(s):  
Yongkun Yang ◽  
Zhen Huang ◽  
Xiaohui Niu ◽  
Hairong Xu ◽  
Yuan Li ◽  
...  

2010 ◽  
Vol 96 (3) ◽  
pp. 310-313 ◽  
Author(s):  
S. Jacopin ◽  
E. Viehweger ◽  
Y. Glard ◽  
F. Launay ◽  
J.-L. Jouve ◽  
...  

2021 ◽  
Vol 21 (3) ◽  
pp. 1250-1258
Author(s):  
Aliekber Yapar ◽  
Ismail Burak Atalay ◽  
Mehmet Ali Tokgoz ◽  
Coskun Ulucakoy ◽  
Bedii Safak Gungor

Objective: To evaluate the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) in giant cell tumor of bone (GCT). Methods: The patients with GCT were identified in the hospital records and pre-treatment complete blood count results were acquired retrospectively. Whether preoperative NLR lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) values had prognostic significance in predicting recurrence was evaluated by Receiver operating curve (ROC) analysis. Furthermore, the prognostic value of NLR was evaluated by Multivariable Cox Regression analysis. Results: There were 96 patients with GCT. It was found that only NLR values had prognostic significance for predicting recurrence (AUC:0.647; 95% CI:0.533-0.762; P=0.021). The statistically significant cut-off value of NLR for predicting re- currence was ≥2.25.NLR was ≥2.25 in 51% (n = 49) of patients. Multivariable analysis showed that NLR ≥2.25 (HR=2.9, 95% CI:1.3-6.6; p=0.009) and lung metastasis (HR=7.9, 95% CI:2.2-28.2; p=0.001) were independent factors of recurrence. In patients with lung metastasis and patients with NLR ≥2.25, recurrence was observed in a sooner period (Log rank test; p=0.001; p=0.009, respectively). Conclusion: Our findings showed that NLR is a new and promising inflammation-based prognostic factor in GCT patients. Keywords: Giant cell tumor of bone; neutrophil-to-lymphocyte ratio; prognostic significance.


1999 ◽  
Vol 47 (12) ◽  
pp. 617-620 ◽  
Author(s):  
Keiko Kitano ◽  
Takeshi Shiraishi ◽  
Kan Okabayashi ◽  
Akinori Iwasaki ◽  
Katsunobu Kawahara ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Zhuo Wang ◽  
Jihui Kang ◽  
Jiayan Lian ◽  
Leilei Huang ◽  
Wenlin Xie ◽  
...  

Osteosarcoma (OS) is the most common primary bone malignancy. Our previous study revealed an association between the level of epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) and the invasion, metastasis, and poor prognosis of OS. However, the exact correlation between the serum EFEMP1 level and OS diagnosis and progression was unclear. This study is aimed at determining the value of the serum EFEMP1 level in the diagnosis and prognosis of OS. Fifty-one consecutive OS patients were prospectively registered in this study. The serum EFEMP1 levels were measured using ELISA at diagnosis, after neoadjuvant chemotherapy, and before and after surgical treatment. Sixty-nine healthy subjects in the control group, nine patients with chondrosarcoma, and 12 patients with giant cell tumor of the bone were also enrolled in this study. Surgical orthotopic implantation was used to generate a mouse OS model, and the correlation between the circulating EFEMP1 levels and tumor progression was examined. Then, OS patients had significantly higher mean serum EFEMP1 levels (7.61 ng/ml) than the control subjects (1.47 ng/ml). The serum EFEMP1 levels were correlated with the Enneking staging system (r=0.32, P=0.021) and lung metastasis (r=0.50, P<0.001). There was also a correlation between the serum EFEMP1 level and EFEMP1 expression in the respective OS samples (r=0.49, P<0.001). Additionally, patients with either chondrosarcoma or giant cell tumor of the bone had significantly higher serum EFEMP1 levels than OS patients. Surgical and chemotherapeutic treatment led to an increase in the serum EFEMP1 levels. Then, the destruction of bone tissues might be one of the factors about the EFEMP1 levels. In the mouse OS model, the serum EFEMP1 level was correlated with tumor progression. Our results suggested that serum EFEMP1 levels might be used to distinguish OS patients from healthy controls and as an indicator for OS lung metastasis. Serum EFEMP1 levels could serve as a new and assisted biomarker for the auxiliary diagnosis and prognosis of OS.


Author(s):  
Rupali Jain ◽  
Chandrashekhara Sh ◽  
Asit Ranjan Mridha

2010 ◽  
Vol 3 (2) ◽  
pp. 72
Author(s):  
Kicheol Kil ◽  
Jinyoung Yoo ◽  
Sun-Young Nam ◽  
Jae-Eun Chung ◽  
Young Lee

1978 ◽  
Vol 114 (6) ◽  
pp. 944-946 ◽  
Author(s):  
D. T. King

2021 ◽  
Vol 60 (1) ◽  
pp. 163-166
Author(s):  
Naji S. Madi ◽  
Said Saghieh ◽  
Ahmad Salah Naja ◽  
Rachid K. Haidar

Sign in / Sign up

Export Citation Format

Share Document